placeholder
UPDATE45
CLINICAL TRIALLimited grounding
Antag Therapeutics to present data on AT7687, its first-in-class GIPR antagonist peptide at the American Diabetes Association’s 2026 Scientific Sessions - BioSpace
Antag Therapeutics will show early data on AT7687, a new peptide drug it's developing to treat diabetes, at a major diabetes conference in 2026. The drug works by blocking a protein called GIPR and is the first of its kind in that category.
Analysis
GIPR antagonism is an emerging counter-thesis to GIP agonism in tirzepatide-class drugs; Antag's AT7687 readout at ADA 2026 will inform whether antagonist mechanism has legs.
- Antag Therapeutics to present AT7687 data at ADA 2026 Scientific Sessions
- AT7687 is described as a first-in-class GIPR antagonist peptide
- Program targets diabetes indication
BioSpace10d
Read